What You Should Know:
- Tempus AI, Inc., a technology company focused on advancing precision medicine with AI, has acquired Paige, an AI company specializing in digital pathology.
- The acquisition, valued at $81.25M, paid predominantly in Tempus common stock, is a strategic move
Read More
M&A: Tempus AI Acquires Digital Pathology Leader Paige for $81.25M
